Xiukun Hou

663 total citations
26 papers, 483 citations indexed

About

Xiukun Hou is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Xiukun Hou has authored 26 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Xiukun Hou's work include Thyroid Cancer Diagnosis and Treatment (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Cancer-related Molecular Pathways (6 papers). Xiukun Hou is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (7 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Cancer-related Molecular Pathways (6 papers). Xiukun Hou collaborates with scholars based in China, United States and South Korea. Xiukun Hou's co-authors include Ming Gao, Xianhui Ruan, Linfei Hu, Xianle Shi, Xiangqian Zheng, Jingtai Zhi, Xi Wei, Xiangqian Zheng, Jingzhu Zhao and Songfeng Wei and has published in prestigious journals such as Nature Communications, ACS Applied Materials & Interfaces and Cell Death and Differentiation.

In The Last Decade

Xiukun Hou

24 papers receiving 479 citations

Peers

Xiukun Hou
Emanuela Minna Italy
Dao Doan United States
Siyang Dong China
Cláudia Miranda Italy
Xiangqian Zheng China
Jianfeng Sang China
Marta De Menna Switzerland
Jason Kirk United States
Valentina Pasquale Italy
Ricardo Soares Portugal
Emanuela Minna Italy
Xiukun Hou
Citations per year, relative to Xiukun Hou Xiukun Hou (= 1×) peers Emanuela Minna

Countries citing papers authored by Xiukun Hou

Since Specialization
Citations

This map shows the geographic impact of Xiukun Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiukun Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiukun Hou more than expected).

Fields of papers citing papers by Xiukun Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiukun Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiukun Hou. The network helps show where Xiukun Hou may publish in the future.

Co-authorship network of co-authors of Xiukun Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiukun Hou. A scholar is included among the top collaborators of Xiukun Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiukun Hou. Xiukun Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tao, Mei, Xianhui Ruan, Wei Luo, et al.. (2025). Enhancer-mediated NR2F2 recruitment activates BGN to promote tumor growth and shape tumor microenvironment in papillary thyroid cancer. Theranostics. 16(1). 298–324. 1 indexed citations
3.
Gu, Pengfei, Jie Zhao, Wei Zhang, et al.. (2024). An Inducible CRISPR‐dCas9‐Based Transcriptional Repression System for Cancer Therapy. Small Methods. 8(8). e2301310–e2301310. 2 indexed citations
4.
Gao, Ying, Xiukun Hou, Yanhui Zhang, et al.. (2024). Multifocality increases the risk of central compartment lymph node metastasis but is not related to the risk of recurrence and death in papillary thyroid carcinoma. Gland Surgery. 13(12). 2383–2394. 1 indexed citations
5.
6.
Shi, Xianle, Yanjing Li, Hongwei Zhou, et al.. (2024). DDX18 coordinates nucleolus phase separation and nuclear organization to control the pluripotency of human embryonic stem cells. Nature Communications. 15(1). 10803–10803. 3 indexed citations
7.
Hou, Xiukun, Junya Ning, Zhongyu Wang, et al.. (2023). PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause. International Journal of Biological Sciences. 19(12). 3970–3986. 5 indexed citations
8.
9.
Hu, Linfei, Kang Ning, Jingtai Zhi, et al.. (2022). Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib. Cell Death and Disease. 13(2). 124–124. 18 indexed citations
10.
11.
Liu, Jianjun, Yang Zhou, Huiying Liu, et al.. (2022). Metabolic reprogramming enables the auxiliary diagnosis of breast cancer by automated breast volume scanner. Frontiers in Oncology. 12. 939606–939606. 5 indexed citations
12.
Zhang, Jun, Bei Sun, Xianhui Ruan, et al.. (2021). Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. Cancer Biology and Medicine. 18(1). 105–119. 8 indexed citations
13.
Hou, Xiukun, Xianle Shi, Wei Zhang, et al.. (2021). LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma. Cell Death and Disease. 12(4). 347–347. 72 indexed citations
14.
Wang, Huijuan, Jingzhu Zhao, Linfei Hu, et al.. (2020). Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway. Frontiers in Oncology. 10. 217–217. 38 indexed citations
15.
16.
Zhang, Jun, Linfei Hu, Huijuan Wang, et al.. (2019). <p>Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma</p>. Cancer Management and Research. Volume 11. 3765–3777. 7 indexed citations
17.
Cao, Xinyi, Xiangqian Zheng, Yi Lu, et al.. (2019). Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma. Thyroid. 29(6). 809–823. 50 indexed citations
18.
Zhi, Jingtai, Yu Wu, Linfei Hu, et al.. (2019). Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma. International Journal of Clinical Oncology. 25(1). 59–66. 13 indexed citations
19.
Wu, Yu, Huijuan Wang, Jingtai Zhi, et al.. (2019). <p>BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients</p>. OncoTargets and Therapy. Volume 12. 6937–6945. 3 indexed citations
20.
Ruan, Xianhui, Xianle Shi, Yang Yu, et al.. (2018). Antitumor effects of anlotinib in thyroid cancer. Endocrine Related Cancer. 26(1). 153–164. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emanuela Minna Breakdown of academic impact, for papers by Dao Doan Breakdown of academic impact, for papers by Siyang Dong Breakdown of academic impact, for papers by Cláudia Miranda Breakdown of academic impact, for papers by Xiangqian Zheng Breakdown of academic impact, for papers by Jianfeng Sang Breakdown of academic impact, for papers by Marta De Menna Breakdown of academic impact, for papers by Jason Kirk Breakdown of academic impact, for papers by Valentina Pasquale Breakdown of academic impact, for papers by Ricardo Soares
Rankless by CCL
2026